A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 23
- Registration Number
- NCT04572152
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇦🇺Alfred Health (The Alfred Hospital), Melbourne, Victoria, Australia
🇦🇺Ashford Cancer Centre, Adelaide, South Australia, Australia
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 6
- Registration Number
- NCT04547101
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Akeso
- Target Recruit Count
- 40
- Registration Number
- NCT04547205
- Locations
- 🇨🇳
The First Affiliated Hospital of Medicine College, Zhejiang University, Hangzhou, Zhejiang, China
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 6
- Registration Number
- NCT04444141
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beiing, China
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 59
- Registration Number
- NCT04444167
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT04380805
- Locations
- 🇺🇸
Womens Cancer Research Foundation, Newport Beach, California, United States
🇺🇸BRCR Medical Center, Plantation, Florida, United States
🇺🇸Maryland Oncology Hematology (Plum Orchard), Silver Spring, Maryland, United States
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 262
- Registration Number
- NCT04358432
- Locations
- 🇨🇳
Zhong Shan Hosipital Fu Dan University, Shanghai, China
🇨🇳Affiliated hospital of Guangdong medical university, Zhanjiang, China
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 34
- Registration Number
- NCT04220307
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Long-term Study of AK102 in Patients With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 796
- Registration Number
- NCT04173403
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 330
- Registration Number
- NCT04173637
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China